Economic Implications of Potential Drug–Drug Interactions in Chronic Pain Patients

Robert Taylor Jr; Joseph V Pergolizzi Jr; R Amy Puenpatom; Kent H Summers


Expert Rev Pharmacoeconomics Outcomes Res. 2013;13(6):725-734. 

In This Article

Association of DDEs & Age

To determine if age was a factor in a patients experience with a DDE, some of the studies grouped and compared different age ranges within OA and cLBP patients.[27,28] When comparing OA versus cLBP in each individual age group (e.g., 35–44 OA vs 35–44 cLBP), prevalence rates were similar between the two pain conditions (Figure 1). For example, patients aged 35–44 years with OA versus cLBP had prevalence rates of 28.1 versus 27.9%, respectively. However, comparison of prevalence rates between different age groups within each pain condition was significantly different. For example, patients with OA in the 35–44 age range (odds ratio [OR]: 1.46; p < 0.001; 95% CI: 1.36–1.56) and in 45–54 age range (OR: 1.50; p < 0.001; 95% CI: 1.43–1.56) had approximately 46% greater risk of DDEs than those aged 65 and older. Patients with cLBP in the 35–44 age range (OR: 1.676; p < 0.001; 95% CI: 1.596–1.761) and in 45–54 age range (OR: 1.690; p < 0.001; 95% CI: 1.621–1.761) had approximately 70% greater risk of DDEs than those aged 65 and older. These studies indicate that many patients are at a risk of experiencing a DDE, but younger patients may be at a greater risk and should be monitored more carefully.

Figure 1.

Prevalence of drug–drug exposuress in osteoarthritis and chronic lower back pain patients across all age groups.
Study population (n) represents those who experienced a DDE.
cLBP: Chronic low back pain; DDE: Drug–drug exposures.
Data taken from [27,28].